Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C

Cancer Immunology, Immunotherapy

Volumn 61, Issue 5, 2012, Pages 713-723

  Snook, Adam E ^a   Magee, Michael S ^a   Marszalowicz, Glen P ^a   Schulz, Stephanie ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer immunotherapy; Cancer mucosa antigens; Cytotoxic T lymphocyte; Guanylyl cyclase C

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; EPITOPE; GAMMA INTERFERON; GUANYLATE CYCLASE; GUANYLATE CYCLASE C; GUANYLATE CYCLASE C VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL LINEAGE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EX VIVO STUDY; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN DOMAIN; TARGET CELL;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; EPITOPES, T-LYMPHOCYTE; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84862503841     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1133-0     Document Type: Article

References (45)

1. DeFrancesco L (2010) Landmark approval for Dendreon's cancer vaccine. Nat Biotechnol 28(6):531-532
2. Snook AE, Eisenlohr LC, Rothstein JL, Waldman SA (2007) Cancer Mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clin Pharmacol Ther 82(6):734-739 (Pubitemid 350114818)
3. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52(3):375-414
4. Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, Waldman SA (1996) Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA 93(25):14827-14832 (Pubitemid 26419054)
5. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA (2005) Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol 36(2):170-179 (Pubitemid 40313574)
6. Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek ME, Birbe R, Palazzo J, Weinberg D, Waldman SA (2006) A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res 12(15):4545-4552 (Pubitemid 44297803)
7. Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, Bonaccorso C, Li Y, Weinberg DS (2009) Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. Jama 301(7):745-752
8. Carlson MR (2009) Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Mol Diagn Ther 13(1):11-14
9. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA (2008) Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst 100(13):950-961 (Pubitemid 351957514)
10. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA (2009) Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res 69(8):3537-3544
11. Cagir B, Gelmann A, Park J, Fava T, Tankelevitch A, Bittner EW, Weaver EJ, Palazzo JP, Weinberg D, Fry RD, Waldman SA (1999) Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med 131(11):805-812
12. Waldman SA, Cagir B, Rakinic J, Fry RD, Goldstein SD, Isenberg G, Barber M, Biswas S, Minimo C, Palazzo J, Park PK, Weinberg D (1998) Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis Colon Rectum 41(3):310-315 (Pubitemid 28141595)
13. Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41(4):178-228
14. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152(1):163-175
15. Einarsdottir T, Lockhart E, Flynn JL (2009) Cytotoxicity and secretion of gamma interferon are carried out by distinct CD8 T cells during Mycobacterium tuberculosis infection. Infect Immun 77(10):4621-4630
16. McKelvey T, Tang A, Bett AJ, Casimiro DR, Chastain M (2004) T-cell response to adenovirus hexon and DNA-binding protein in mice. Gene Ther 11(9):791-796 (Pubitemid 38659758)
17. Oehen S, Brduscha-Riem K (1998) Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 161(10):5338-5346 (Pubitemid 28519094)
18. Aichele P, Brduscha-Riem K, Oehen S, Odermatt B, Zinkernagel RM, Hengartner H, Pircher H (1997) Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6(5):519-529 (Pubitemid 27239343)
19. Li Z, Zhang M, Zhou C, Zhao X, Iijima N, Frankel FR (2008) Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J Immunol 180(4):2504-2513
20. Buckwalter MR, Srivastava PK (2008) "It is the antigen(s), stupid"and other lessons from over a decade of vaccitherapy of human cancer. Semin Immunol 20(5):296-300
21. Carrithers SL, Parkinson SJ, Goldstein S, Park P, Robertson DC, Waldman SA (1994) Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology 107(6):1653-1661
22. Conzelmann M, Dieterle CP, Linnemann U, Berger MR (2003) Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients. Int J Cancer 107(4):617-628 (Pubitemid 37296124)
23. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D (2002) Projection of an immunological self shadow within the thymus by the aire protein. Science 298(5597):1395-1401 (Pubitemid 35346134)
24. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684):480-483
25. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684):478-480
26. Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393(6684):474-478
27. Buller RM, Holmes KL, Hugin A, Frederickson TN, Morse HC III (1987) Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature 328(6125):77-79 (Pubitemid 17103585)
28. Rahemtulla A, Fung-Leung WP, Schilham MW, Kundig TM, Sambhara SR, Narendran A, Arabian A, Wakeham A, Paige CJ, Zinkernagel RM et al (1991) Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353(6340):180-184 (Pubitemid 21912486)
29. Wu Y, Liu Y (1994) Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T-cell help in CD8+ T-cell responses. Current biology: CB 4(6):499-505
30. Vezys V, Olson S, Lefrancois L (2000) Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction. Immunity 12(5):505-514
31. Vezys V, Lefrancois L (2002) Cutting edge: inflammatory signals drive organ-specific autoimmunity to normally cross-tolerizing endogenous antigen. J Immunol 169(12):6677-6680 (Pubitemid 36899250)
32. Liu Z, Lefrancois L (2004) Intestinal epithelial antigen induces mucosal CD8 T cell tolerance, activation, and inflammatory response. J Immunol 173(7):4324-4330 (Pubitemid 39280660)
33. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR (1998) Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188(2):409-414 (Pubitemid 28357770)
34. Titu LV, Monson JR, Greenman J (2002) The role of CD8(+) T cells in immune responses to colorectal cancer. Cancer Immunol Immunother 51(5):235-247 (Pubitemid 34810704)
35. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27(35):5944-5951
36. Galon J, Fridman WH, Pages F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67(5):1883-1886 (Pubitemid 46424201)
37. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960-1964 (Pubitemid 44498003)
38. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654-2666 (Pubitemid 41817714)
39. Mocellin S, Rossi CR, Lise M, Nitti D (2004) Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology 127(6):1821-1837 (Pubitemid 39575861)
40. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12(11):3416-3424
41. Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, Craig D, Arani RB, Schlom J, LoBuglio AF (1999) Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 5(9):2330-2337 (Pubitemid 29437310)
42. Nagorsen D, Thiel E (2006) Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12(10):3064-3069 (Pubitemid 43837352)
43. Colorectal Cancer (2003) In: Stewart BW, Kleihues P (eds) World cancer report. International Agency for Research on Cancer, Lyon, pp 198-202
44. Schafer H, Schafer A, Kiderlen AF, Masihi KN, Burger R (1997) A highly sensitive cytotoxicity assay based on the release of reporter enzymes, from stably transfected cell lines. J Immunol Methods 204(1):89-98 (Pubitemid 27192315)
45. Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225(4669):1487-1489 (Pubitemid 14033135)